Status:
TERMINATED
Using the Neuroscience of Fear Extinction for Anxiety Reduction
Lead Sponsor:
Stanford University
Conditions:
Social Anxiety
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
Social anxiety disorder affects as many as 12% of Americans, resulting in significant distress and disability. Although exposure therapy is one of the best treatments available, as many as 25% of pati...
Detailed Description
The best available treatment for social anxiety disorder is exposure therapy; however, 25% of socially anxious patients do not respond to an adequate course of exposure therapy and it is unclear why. ...
Eligibility Criteria
Inclusion
- age 18-50
- primary diagnosis of social anxiety disorder
- fluent spoken and written English
- able to provide informed consent.
Exclusion
- history of mania or psychosis
- current moderate or severe substance use disorder
- current major depression greater than moderate severity
- high risk for suicide
- prior traumatic brain injury with loss of consciousness \>5 minutes
- general medical condition or impediment to vision, hearing, or motor function likely to interfere with assessments
- prior exposure therapy (\>2 sessions)
- current use of psychotropic medication
- current psychotherapy other than couples counseling
- post-menopausal status
- pregnancy
Key Trial Info
Start Date :
January 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2021
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT03465137
Start Date
January 14 2018
End Date
September 30 2021
Last Update
October 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University Department of Psychiatry & Behavioral Sciences
Palo Alto, California, United States, 94304